Oncopharmpod
Futibatinib, ESR1, & GPRC5D
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:16:05
- More information
Informações:
Synopsis
A new FGFR inhibitor, futibatinib, is approved. Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight. What the heck is GPRC5D (rhymes with CAR-T)? PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1 GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900
